The Measurement of Heparin and Other Therapeutic Sufphated Polysaccharides in Plasma, Serum and Urine

Summary

The competitive binding assay described will specifically and accurately measure concentrations of administered heparin in biological fluids with a sensitivity of 60 ng ml-1. Neither endogenous glycosaminoglycans, nor plasma proteins such as ATIII and PF4 interfere in the assay. Semi-synthetic highly sulphated heparinoids and LMW heparin can also be measured. Using this assay heparin clearance followed simple first-order kinetics over the dose range 100-5,000 units, but the half-life was strongly dose-dependent. There was good correlation with heparin activity measurements by APTT and anti-Xa clotting assays. Plasma concentrations were measurable for at least 5 h following subcutaneous injection of 10,000 units of heparin. Excretion in the urine could be followed after all but the lowest intravenous dose. This assay, used in conjunction with measurements of heparin anticoagulant activity, will be valuable in the elucidation of mechanisms of action of heparin and the heparinoids, and in the assessment and management of problems related to heparin therapy.

Keywords

Heparin - Heparinoids - Competitive binding assay - Clearance - Volunteer studies

• References

• 1 Lee RI, White PD. A clinical study of the coagulation time of blood. Am J Med Sci 1913; 145: 495-503
• 2 Thomson JM. A Practical Guide to Blood Coagulation and Haemostasis. Churchill, London 1970; 1-369
• 3 Andersson LO, Barrowcliffe TW, Homer E, Johnson EA, Sims GE C. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583
• 4 Eika C, Godal HC, Kierulf P. Detection of small amounts of heparin by the thrombin clotting time. Lancet 1972; 2: 376
• 5 Yin ET, Wessler S, Butler JV. Plasma heparin: a unique, practical, submicrogram-sensitive assay. J Lab Clin Med 1973; 81: 298-310
• 6 Teien AN, Lie M, Abilgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416
• 7 Godal HC. Heparin assay methods for control of in vivo heparin effect. Thrombes Diathes Haemorrh 1975; 33: 77-80
• 8 Teien AN, Lie M. Heparin assay in plasma: a comparison of five clotting methods. Thromb Res 1975; 7: 777-788
• 9 Lane DA, Michalski R, van Ross ME, Kakkar VV. Comparison of heparin and a semisynthetic heparin analogue, A 73025. Br J Haematol 1977; 37: 239-245
• 10 Fischer AM, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate (SP54) and heparin. I: mechanism of action on blood coagulation. Thromb Haemostas 1982; 47: 104-108
• 11 Torngren S, Noren I, Forsskahl B, Sipila H. Effects of heparin and a semisynthetic heparin analogue on platelet aggregation, lipoprotein lipase and other laboratory tests in surgical patients. Thromb Res 1983; 30: 527-34
• 12 Thomas DP, Morton RE. A low molecular weight heparin compared with unfractionated heparin. Thromb Res 1982; 28: 343-350
• 13 Dawes J, Pepper DS. A sensitive competitive binding assay for exogenous and endogenous heparins. Thromb Res 1982; 27: 387-396
• 14 Dawes J, Pepper DS. Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-860
• 15 Greenwood FC, Hunter WM, Glover JS. The preparation of ¹³¹I-labelled human growth hormone of high specific radio activity. Biochem J 1963; 89: 114-123
• 16 Hunter WM. Simplified solid-phase radioimmunoassay without centrifugation. Acta Endocrinol 1977; 85 Suppl (Suppl. 212) 463
• 17 Dawes J, Smith RC, Pepper DS. The release, distribution and clearance of human β-thromboglobulin and platelet factor 4. Thromb Res 1978; 12: 851-861
• 18 Levy SW, Jaques LB. Appearance of heparin antithrombin-active chains in vivo after injection of commercial heparin and in anaphylaxis. Thromb Res 1978; 13: 429-441
• 19 Gundry SR, Klein MD, Drongowski RA, Kirsh MM. Clinical evaluation of a new rapid heparin assay using the dye azure A. Am J Surg 1984; 148: 191-194
• 20 Johnson EA, Mulloy B. Simple metachromatic assay methods for heparin and protamine. J Pharm Pharmacol 1976; 28: 836-837
• 21 Godal HC. A comparison of two heparin-neutralising agents, protamine and polybrene. Scand J Clin Lab Invest 1960; 12: 446-457
• 22 Calatroni A, Donnelly PV, di Ferrante N. The glycosaminoglycans of human plasma. J Clin Invest 1969; 48: 332-343
• 23 Varadi DP, Cifonelli JA, Dorman A. The acid mucopolysaccharides in normal urine. Biochim Biophys Acta 1967; 141: 103-117
• 24 Estes JW, Poulin PF. Pharmacokinetics of heparin. Clin Pharmacokinetics 1980; 5: 204-220
• 25 Estes JW, Poulin PF. Pharmacokinetics of heparin. Distribution and elimination. Thrombos Diathes Haemorrh 1974; 33: 26-37
• 26 Levine SP, Sorenson RR, Harris MA, Knieriem LK. The effect of platelet factor 4 (PF4) on assays of plasma heparin. Br J Haematol 1984; 57: 585-596
• 27 Kraemer PM. Heparin releases heparan sulphate from the cell surface. Biochem Biophys Res Comm 1977; 78: 1334-1340
• 28 Cade JF, Buchanan MR, Boneu B, Ockleford P, Carter CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984; 35: 613-625
• 29 MacGregor IR, Dawes J, Pepper DS, Prowse CV, Stocks J. Metabolism of sodium pentosan polysulphate in man measured by a new competitive binding assay for sulphated polysaccharides - comparison with effects upon anticoagulant activity, lipolysis and platelet α-granule proteins. Thromb Haemostas 1985; 53: 411-414
• 30 Simon TL, Hyers TM, Gaston JP, Harker LA. Heparin pharmacokinetics: increased requirements in pulmonary embolism. Br J Haematol 1978; 39: 111-120
• 31 de Swart CAM, Nijkeyer B, Roelofs J MM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982; 60: 1251-1258
• 32 Estes JW, Pelikan EW, Kruger-Thiemere K-T. A retrospective study of the pharmacokinetics of heparin. Clin Pharmacol Ther 1969; 10: 329-337
• 33 Barrowcliffe TW, Johnson EA, Eggleton CA, Thomas DP. Anticoagulant activities of lung and mucous heparins. Thromb Res 1977; 12: 27-36
• 34 Thomas DP, Barrowcliffe TW, Merton RE, Stocks J, Dawes J, Pepper DS. In vivo release of anti-Xa clotting activity by a heparin analogue. Thromb Res 1980; 17: 831-840
• 35 Thomas DP. Heparin, low molecular weight heparin, and heparan analogues. Br J Haematol 1984; 58: 385-390